Why Tandem Diabetes Care Stock Is Back on Investor Radars

Tandem Diabetes Care (TNDM) has drawn fresh attention after recent share price swings, with the stock up about 29% over the past month but down roughly 24% in the past 3 months.

At a share price of $16.60, Tandem Diabetes Care has seen a 5.06% 1 day share price gain and a 29.49% 30 day share price return. This follows a 24.24% 90 day decline and a 22.97% year to date share price decline, while the 1 year total shareholder return is down 20.04%. Together, these figures point to short term momentum after a weaker longer term stretch.

If you are looking beyond a single healthcare stock and want more ideas at the intersection of medicine and data, this is a good time to scan 40 healthcare AI stocks

With Tandem Diabetes Care trading at $16.60, carrying a value score of 5 and sitting well below an analyst price target of $29.20, the question is whether this represents a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 43.2% Undervalued

At $16.60, the most followed narrative on Tandem Diabetes Care is anchored to a fair value of $29.20, built on detailed revenue and earnings projections using an 8.51% discount rate.

Broader pharmacy channel expansion and acceleration of pharmacy-based supply sales are expected to lower out-of-pocket costs, increase pump adoption rates, and shift more high-margin recurring supply sales through premium-priced channels, supporting future revenue growth, margin expansion, and improved earnings.

Read the complete narrative. Read the complete narrative.

Want to see what justifies that higher fair value? The narrative leans heavily on recurring pump supplies, overseas direct sales, and a sharp swing in margins and earnings. Curious which assumptions really move the valuation?

Result: Fair Value of $29.20 (UNDERVALUED)

However, this hinges on Tandem offsetting competitive pressure in insulin pumps and avoiding setbacks as it expands into more complex pharmacy and international distribution channels.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

The message here highlights that both risks and rewards are on the table, so consider acting promptly, review the details carefully, and weigh the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop here, you risk missing other stocks that fit your style, so take a few minutes to line up fresh ideas built on hard numbers.

• Target higher quality opportunities by scanning 44 high quality undervalued stocks. This tool combines solid fundamentals with prices that may not fully reflect their financial profile.
• Prioritize staying power by checking solid balance sheet and fundamentals stocks screener (48 results) to spot companies with stronger finances that could better handle business pressures.
• Get ahead of the crowd by reviewing the screener containing 20 high quality undiscovered gems before other investors start paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.